Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs Roivant Sciences Ltd. Common Shares (ROIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AI & Tech Portfolio Option Income ETF vs Roivant Sciences Ltd. Common Shares — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $42.99 (market cap $135.69M), while Roivant Sciences Ltd. Common Shares trades at $35.44 (market cap $24.72B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 182.2× YieldMax AI & Tech Portfolio Option Income ETF's market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, YieldMax AI & Tech Portfolio Option Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax AI & Tech Portfolio Option Income ETF for 61 Days and Roivant Sciences Ltd. Common Shares for 1 Days on average.
| GPTY | ROIV | |
|---|---|---|
Market Cap | $135.69M | $24.72B |
Volume | 97,442 | 6,279,442 |
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $41.81 |
52-Week Low | $34.73 | $16.04 |
Typical Hold Time | 61 Days | 1 Days |
Enterprise Value | — | $20.99B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →About Roivant Sciences Ltd. Common Shares
Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →
